Korean J Med > Volume 76(2); 2009 > Article
The Korean Journal of Medicine 2009;76(2):137-142.
The NCCN clinical practice guidelines and best supportive care for the myelodysplastic syndromes
Chul Won Choi
골수이형성증의 NCCN 치료지침과 최적의 보조요법
최철원
Abstract
The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem-cell disorders characterized by peripheral cytopenias and hypercellular, dysplastic bone marrow. Appropriate treatment of cytopenia, as well as of other related complications, affect the overall survival of patients. The best supportive care including red blood cell or platelet transfusions and antibiotics have been the most frequent treatment given for patients with MDS. Now new drugs have recently been approved for treating specific subtypes of MDS. Because the choice of therapy and the decision to begin treatment must be tailored to each patient, specific practice guidelines based on extensive evaluation of the data are warranted for both patients and treating physicians. Here, the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for the MDS and currently available options for the best supportive care have been reviewed. (Korean J Med 76:137-142, 2009)
Key Words: Myelodysplastic syndromes; Practice guideline


TOOLS
METRICS Graph View
  • 1,452 View
  • 23 Download

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2024 by The Korean Association of Internal Medicine.

Developed in M2PI

Close layer
prev next